ID: ALA399007

Max Phase: Preclinical

Molecular Formula: C22H32BrN3O3

Molecular Weight: 466.42

Molecule Type: Small molecule

Representations

Canonical SMILES:  COC(=O)[C@H](Cc1cnc[nH]1)NC(=O)/C=C/C(C)(C)C/C=C(\C)CC/C=C(\C)Br

Standard InChI:  InChI=1S/C22H32BrN3O3/c1-16(7-6-8-17(2)23)9-11-22(3,4)12-10-20(27)26-19(21(28)29-5)13-18-14-24-15-25-18/h8-10,12,14-15,19H,6-7,11,13H2,1-5H3,(H,24,25)(H,26,27)/b12-10+,16-9+,17-8+/t19-/m0/s1

Standard InChI Key:  XBBMUPXDWVQMOZ-ZGXSERFNSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 466.42

Molecular Weight (Monoisotopic): 465.1627

AlogP: 4.61

#Rotatable Bonds: 11

Polar Surface Area: 84.08

Molecular Species: NEUTRAL

HBA: 4

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.64

CX Basic pKa: 6.74

CX LogP: 3.59

CX LogD: 3.53

Aromatic Rings: 1

Heavy Atoms: 29

QED Weighted: 0.28

Np Likeness Score: 0.61

References

1. Kitayama T, Iwabuchi R, Minagawa S, Sawada S, Okumura R, Hoshino K, Cappiello J, Utsumi R..  (2007)  Synthesis of a novel inhibitor against MRSA and VRE: preparation from zerumbone ring opening material showing histidine-kinase inhibition.,  17  (4): [PMID:17157007] [10.1016/j.bmcl.2006.11.015]

Source

Source(1):

• Scientific Literature